{"id":"W1935026499","doi":"10.1158/1538-7445.sabcs14-pd2-2","title":"Abstract PD2-2: Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital du Saint-Sacrement; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Bevacizumab; Breast cancer; Internal medicine; Hazard ratio; Oncology; Taxane; Triple-negative breast cancer; Population; Anthracycline; Randomized controlled trial; Adjuvant therapy; Cancer; Chemotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004065109,0.0007789599,0.001367358,0.0001990686,0.0002811178,0.001229672,0.0006387015,0.0009862394,0.003291707],"category_scores_gemma":[0.003635323,0.0003072845,0.001527899,0.0002942701,0.0004574001,0.0005490363,0.0004666049,0.002507546,0.0005633933],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006965747,"about_ca_system_score_gemma":0.0006995728,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006018388,"about_ca_topic_score_gemma":0.001359666,"domain_scores_codex":[0.9982203,0.00118979,0.00007955575,0.0002106162,0.0001961811,0.0001034211],"domain_scores_gemma":[0.9980342,0.0005530836,0.0005150657,0.0001934125,0.0002272504,0.0004770421],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9196309,0.004679671,0.005727911,0.0009914826,0.006450295,0.0001003051,0.00007256114,0.001244237,0.005101416,0.000365349,0.01003138,0.04560437],"study_design_scores_gemma":[0.8872181,0.06844346,0.02683333,0.0001421379,0.005564411,0.0001742472,0.00004425549,0.001622232,0.002116082,0.0007597329,0.007032784,0.0000493275],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9589637,0.01713252,0.001699282,0.002719896,0.0007037441,0.002748585,0.007245263,0.0001255892,0.008661423],"genre_scores_gemma":[0.9788896,0.002649539,0.001723233,0.002312736,0.0004950812,0.001588291,0.008733138,0.0000347376,0.003573645],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004065109,"threshold_uncertainty_score":0.02149862,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2864954876726006,"score_gpt":0.5366607232827357,"score_spread":0.2501652356101351,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}